LBRX — LB PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1691082 ·
Last close
$28.33
Market Cap
$812.41M
52W High
$33.47
52W Low
$22.20
ADV30
212,169
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -22,104,000 | -19,054,000 | 393,482,000 | 320,676,000 | 14,789,000 |
| Dec 2025 | 0 | — | -13,870,000 | -11,472,000 | 312,934,000 | 250,173,000 | 11,624,000 |
| Sep 2025 | 0 | — | -5,246,000 | -3,556,000 | 320,746,000 | 269,744,000 | 10,525,000 |
| Jun 2025 | — | — | — | — | 19,248,000 | 14,225,000 | 123,121,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-49,178,000
Investing CF
$-2,464,000
Financing CF
$302,582,000
CapEx
$-721,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.07
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-129,528,000
Inventory
—
Receivables
—
ST Investments
$45,040,000
EBIT TTM
$-39,009,000
Pretax Income TTM
$-34,278,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -30,404,000 | -25,205,000 | 312,934,000 | 11,624,000 | — | -35,208,000 |
| Dec 2024 | 0 | -64,830,000 | -63,102,000 | 33,534,000 | 128,088,000 | — | -53,052,000 |
| Dec 2023 | 0 | -11,376,000 | -6,275,000 | 45,657,000 | 80,130,000 | — | -12,094,000 |
| Dec 2022 | 0 | -2,809,000 | -14,348,000 | 21,492,000 | 50,304,000 | — | -2,728,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.49
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPRY | ARS Pharmaceuticals, Inc. | $811.31M | $8.17 | — |
| GERN | GERON CORP | $821.15M | $1.28 | — |
| CTMX | CytomX Therapeutics, Inc. | $803.32M | $3.69 | — |
| ESPR | Esperion Therapeutics, Inc. | $803.19M | $3.12 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $829.39M | $18.81 | — |
News headlines (Yahoo Finance, 1h cache)
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
2026-05-26 16:00 · Yahoo
LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans
2026-05-14 11:02 · Yahoo
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 20:05 · Yahoo
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
2026-04-22 20:05 · Yahoo
LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham
2026-04-17 02:03 · Yahoo
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
2026-04-09 20:05 · Yahoo
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Re
2026-03-27 16:00 · Yahoo
LB Pharmaceuticals Inc.: Q4 Earnings Snapshot
2026-03-26 20:21 · Yahoo
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-03-26 20:05 · Yahoo
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
2026-03-25 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.